TCM
NKTR icon

Tekla Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Tekla Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-22,320
Closed -$4.04M – 107
2014
Q3 		$4.04M Buy
+22,320
New +$4.27M 0.19% 91

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Tekla Capital Management's NKTR Position: Q3 2021 in Review

Tekla Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 12,029 shares — an estimated $3.1M sold.

Tekla Capital Management first reported a position in NKTR in Q3 2014 and held it in 15 quarters. The position peaked at $13.2M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Tekla Capital Management reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 12,029 Nektar Therapeutics shares in Q3 2021, an estimated $3.1M.
  • Tekla Capital Management first reported a position in Nektar Therapeutics in Q3 2014 and held it in 15 quarters.
  • Tekla Capital Management's Nektar Therapeutics position peaked at $13.2M in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.